 |
50 Diseases |  |
65 Trials |
|
65 Trials |  |
4287 News |  |
| «12...38394041424344454647484950» |
- ||| Avastin (bevacizumab) / Roche, Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial initiation date, Metastases: Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma (clinicaltrials.gov) - Aug 15, 2013
P2, N=180, Recruiting, Sponsor: Melanoma Research Foundation Breakthrough Consortium
Initiation date: Jun 2012 --> Aug 2013
- |||| Avastin (bevacizumab) / Roche, Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment open, Metastases: Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma (clinicaltrials.gov) - Aug 15, 2013
P2, N=180, Recruiting, Sponsor: Melanoma Research Foundation Breakthrough Consortium
Initiation date: Jun 2012 --> Aug 2013 Not yet recruiting --> Recruiting
- ||| Zelboraf (vemurafenib) / Roche
Enrollment open, Metastases: A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy (clinicaltrials.gov) - Aug 12, 2013
P1, N=64, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Zelboraf (vemurafenib) / Roche
Trial initiation date: A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) (clinicaltrials.gov) - Aug 4, 2013
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Initiation date: Apr 2013 --> Jul 2013
- Zelboraf (vemurafenib) / Roche
Enrollment open, Metastases: A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies (clinicaltrials.gov) - Jul 28, 2013
P1, N=32, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Apr 2013 --> Jul 2013 Not yet recruiting --> Recruiting
- | Zelboraf (vemurafenib) / Roche
New P1 trial, Metastases: A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Jul 25, 2013
P1, N=46, Active, not recruiting, Sponsor: Hoffmann-La Roche
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zelboraf (vemurafenib) / Roche
Enrollment open, Metastases: Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor (clinicaltrials.gov) - Jul 17, 2013
P1/2, N=71, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Zelboraf (vemurafenib) / Roche
New P2 trial, Metastases: Treatment of patients with advanced melanoma with chemotherapy + Interferon combined with vemurafenib (BRAF-mutation positive patients) or chemotherapy +Interferon (BRAF-mutation negative patients) Paikallisesti levinneen tai et (EUDRACT) - Jul 14, 2013
P2, N=120, Ongoing, Sponsor: Finnish melanoma group
- ||||| Zelboraf (vemurafenib) / Roche
New P4 trial, Metastases: An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma (clinicaltrials.gov) - Jul 10, 2013
P4, N=60, Recruiting, Sponsor: Hoffmann-La Roche
- Zelboraf (vemurafenib) / Roche
New P1 trial, Metastases: A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (clinicaltrials.gov) - Jul 9, 2013
P1, N=24, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- Zelboraf (vemurafenib) / Roche
Enrollment open, Metastases: A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (clinicaltrials.gov) - Jul 8, 2013
P1, N=24, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Zelboraf (vemurafenib) / Roche
Metastases: A Study of Vemurafenib in Participants With Metastatic Melanoma (clinicaltrials.gov) - Jul 2, 2013
P4, N=3239, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New P1/2 trial, Metastases: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (clinicaltrials.gov) - Jun 10, 2013
P1/2, N=20, Recruiting, Sponsor: University of Iowa
- ||| Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases (clinicaltrials.gov) - Jun 9, 2013
P2, N=146, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Combination therapy, Metastases: Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib (clinicaltrials.gov) - May 30, 2013
P2, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial initiation date, Combination therapy, Metastases: A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma (clinicaltrials.gov) - May 22, 2013
P1, N=131, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Initiation date: Aug 1973 --> Feb 2011
- ||| Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation (clinicaltrials.gov) - May 22, 2013
P2, N=51, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Aug 1973 --> Feb 2011 Recruiting --> Active, not recruiting
- Zelboraf (vemurafenib) / Roche
Enrollment open, Metastases: A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy (clinicaltrials.gov) - May 12, 2013
P1, N=32, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Zelboraf (vemurafenib) / Roche
New P1 trial, Metastases: A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy (clinicaltrials.gov) - May 9, 2013
P1, N=32, Recruiting, Sponsor: Hoffmann-La Roche
- ||| Zelboraf (vemurafenib) / Roche
New P1 trial, Metastases: A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy (clinicaltrials.gov) - May 6, 2013
P1, N=64, Recruiting, Sponsor: Hoffmann-La Roche
- | Zelboraf (vemurafenib) / Roche
Enrollment open: Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases (clinicaltrials.gov) - May 1, 2013
P2, N=34, Recruiting, Sponsor: Yale University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Zelboraf (vemurafenib) / Roche
New P1 trial, Metastases: A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies (clinicaltrials.gov) - Apr 29, 2013
P1, N=32, Recruiting, Sponsor: Hoffmann-La Roche
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New P1 trial, Metastases: Radiation Use During Vemurafenib Treatment (clinicaltrials.gov) - Apr 29, 2013
P1, N=36, Not yet recruiting, Sponsor: University of Utah
- ||||| voruciclib (P1446A-05) / MEI, Zelboraf (vemurafenib) / Roche
New P1/2 trial, Metastases: Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation (clinicaltrials.gov) - Apr 24, 2013
P1/2, N=100, Recruiting, Sponsor: Piramal Enterprises Limited
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen, Zelboraf (vemurafenib) / Roche
New P1 trial, Surgery, Metastases: Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery (clinicaltrials.gov) - Apr 16, 2013
P1, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
- Zelboraf (vemurafenib) / Roche
Enrollment open: A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) (clinicaltrials.gov) - Apr 16, 2013
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Turalio (pexidartinib) / Daiichi Sankyo, Zelboraf (vemurafenib) / Roche
New P1 trial, Combination therapy, Metastases: A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma (clinicaltrials.gov) - Apr 4, 2013
P1, N=90, Recruiting, Sponsor: Plexxikon
- ||||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Trial initiation date, Metastases: COMBI-v: Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (clinicaltrials.gov) - Mar 27, 2013
P3, N=694, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Initiation date: Jan 2012 --> Jun 2012
- Zelboraf (vemurafenib) / Roche
Clinical: A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants (clinicaltrials.gov) - Mar 24, 2013
P1, N=16, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jan 2012 --> Jun 2012 Not yet recruiting --> Recruiting
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New P2 trial, IO biomarker, Metastases: The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma (clinicaltrials.gov) - Mar 14, 2013
P2, N=15, Recruiting, Sponsor: Georgetown University
- Zelboraf (vemurafenib) / Roche
Trial termination, Metastases: Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation (clinicaltrials.gov) - Mar 13, 2013
P2, N=2, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Terminated; Lack of accrual
- Zelboraf (vemurafenib) / Roche
Enrollment change, Metastases: Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation (clinicaltrials.gov) - Mar 13, 2013
P2, N=2, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Terminated; Lack of accrual N=22 --> 2
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment open, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 14, 2013
P1, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=22 --> 2 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
New P1 trial, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 6, 2013
P1, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Zelboraf (vemurafenib) / Roche
New P2 trial: Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases (clinicaltrials.gov) - Jan 29, 2013
P2, N=34, Recruiting, Sponsor: Yale University
- | Herceptin (trastuzumab) / Roche, Zelboraf (vemurafenib) / Roche
New P2 trial: SHIVA: A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer (clinicaltrials.gov) - Jan 16, 2013
P2, N=1000, Recruiting, Sponsor: Institut Curie
- | Zelboraf (vemurafenib) / Roche
New P1 trial: A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants (clinicaltrials.gov) - Jan 10, 2013
P1, N=16, Recruiting, Sponsor: Hoffmann-La Roche
- | Zelboraf (vemurafenib) / Roche
New P1 trial, Metastases: A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma (clinicaltrials.gov) - Jan 8, 2013
P1, N=29, Active, not recruiting, Sponsor: Hoffmann-La Roche
- Zelboraf (vemurafenib) / Roche
New P1 trial, Metastases: A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma (clinicaltrials.gov) - Jan 8, 2013
P1, N=40, Suspended, Sponsor: Hoffmann-La Roche
- | Zelboraf (vemurafenib) / Roche
New P1 trial: A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) (clinicaltrials.gov) - Jan 8, 2013
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
- ||| sonolisib (PX 866) / Pfizer
Trial initiation date, Metastases: Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma (clinicaltrials.gov) - Jan 7, 2013
P1/2, N=146, Active, not recruiting, Sponsor: Oncothyreon Inc.
Not yet recruiting --> Recruiting Initiation date: May 2012 --> Aug 2012
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zelboraf (vemurafenib) / Roche
Enrollment open, IO biomarker: Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma (clinicaltrials.gov) - Jan 3, 2013
P2, N=49, Recruiting, Sponsor: Massachusetts General Hospital
Initiation date: May 2012 --> Aug 2012 Not yet recruiting --> Recruiting
- Zelboraf (vemurafenib) / Roche
Enrollment change, Metastases: A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma (clinicaltrials.gov) - Jan 2, 2013
P1, N=15, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=12 --> 15
- Zelboraf (vemurafenib) / Roche
Enrollment open, Metastases: BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations (clinicaltrials.gov) - Jan 2, 2013
P1, N=27, Recruiting, Sponsor: Hoffmann-La Roche
N=12 --> 15 Not yet recruiting --> Recruiting
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zelboraf (vemurafenib) / Roche
New P2 trial, IO biomarker: Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma (clinicaltrials.gov) - Dec 19, 2012
P2, N=49, Recruiting, Sponsor: Massachusetts General Hospital
- Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Enrollment open, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - Dec 17, 2012
P1, N=114, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Metastases: Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) (clinicaltrials.gov) - Dec 13, 2012
P1, N=50, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Zelboraf (vemurafenib) / Roche
New P4 trial: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol (clinicaltrials.gov) - Nov 29, 2012
P4, N=450, Recruiting, Sponsor: Hoffmann-La Roche
- Enrollment change, Combination therapy, Metastases: Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib (clinicaltrials.gov) - Nov 18, 2012
P2, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=72 --> 36
- |||||| Zelboraf (vemurafenib) / Roche
Enrollment open: BRIM8: A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma (clinicaltrials.gov) - Nov 11, 2012
P3, N=725, Recruiting, Sponsor: Hoffmann-La Roche
N=72 --> 36 Not yet recruiting --> Recruiting